



Xellia Pharmaceuticals Welcomes Dignitaries from Hungarian Ministry of Foreign Affairs and Trade and Hungarian Embassy to Copenhagen Headquarters

Copenhagen, Denmark, and Budapest, Hungary - 31 May 2016 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today welcomed a delegation from the Hungarian Ministry of Foreign Affairs and Trade, and the Hungarian Embassy to its Copenhagen headquarters during their official visit to Denmark.

The dignitaries included Mr. Péter Szijjártó, Minister of Foreign Affairs and Trade, Mr. László Hellebrandt, Ambassador of Hungary to Denmark, Mr. Kristóf Altusz, Deputy State Secretary for European and American Affairs from the Ministry for Foreign Affairs and Trade, Mr. Róbert Ésik, President of the Hungarian Investment Promotion Agency and Mr. Domonkos Lakner, Economic Attaché, Embassy of Hungary.

The visit follows the recent announcement of the expansion of Xellia's Budapest facility with a new USD\$10 million Centralized Laboratory Services building which will create 80 new roles in addition to the 200 employees currently at the site. Xellia's CEO Carl-Åke Carlsson gave a presentation explaining the reasons for choosing to locate the new building in Hungary. He also outlined the Company's portfolio and pipeline of anti-infectives, and the important role that these drugs play in the global fight against antimicrobial resistance.

The delegation also toured Xellia's manufacturing and commercial facilities and met with employees during the visit.

Carl-Åke Carlsson, CEO, Xellia said: "It was an honor to welcome the Hungarian delegation to our headquarters and to have the opportunity to discuss our continued commitment to, and investment in the Budapest site. This visit both celebrates the strong relationship that we have built with the Hungarian Government and academic centers in the almost 20 years that we have been operating in the country, and establishes the importance of Budapest in our global strategy."

- Ends -

For more information, please contact:

Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00

Zsolt Nemeth, General Manager, Budapest
Tel: +36 1 260 4130

Instinctif Partners (media relations)

Jen Lewis / Eileen Paul / Melanie Toyne-Sewell

Tel: +44 (0)1260 296 500

Email: xellia@instinctif.com

About Xellia

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,200 people.

Xellia is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.

Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.

Further information about Xellia can be found at: www.xellia.com.